Catalyst Event
Eli Lilly and Co (LLY) · Earnings Release
From KEDI U.S. Medical AI Index (KUSMAI)
4/30/2026, 12:00:00 AM
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
Korean Translation
1% 이상의 주가 변동이 예상되는 2026년 1분기 실적 발표 예정됨.
Related Recent Events
Intuitive Surgical Inc (ISRG) · Earnings Release
Q1 2026 earnings release is scheduled.
4/21/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
New target action date for the FDA's decision on oral obesity drug orforglipron, following an extension of the review period announced on January 15, 2026, scheduled; a price impact of at least 1% is expected.
4/10/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Other
The company is scheduled to present five studies at the 2026 USCAP Annual Meeting from 2026-03-21 to 2026-03-26 scheduled.
3/21/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Announced positive topline results from the TRANSCEND-T2D-1 Phase 3 trial for its investigational drug retatrutide, which showed significant reductions in A1C and body weight for adults with type 2 diabetes; a price impact of over 10% is estimated.
3/19/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Other
Appeals court ruling on whistleblower lawsuit regarding 340B program overcharging allegations scheduled for March 18, 2026; moderate impact expected from potential legal liabilities, scheduled.
3/18/2026, 12:00:00 AM
Adaptive Biotechnologies Corp (ADPT) · Other
President and COO Julie Rubinstein sold 57,180 shares between March 16 and March 18, 2026, for a total of approximately $762,000 under a pre-arranged 10b5-1 trading plan.
3/18/2026, 12:00:00 AM